Adlai Nortye names Archie Tse president as Kaiyang Tang retires

Reuters04-02 04:34
Adlai Nortye names Archie Tse president as Kaiyang Tang retires
  • Adlai Nortye appointed Archie Tse as president effective April 1, 2026, while he continues as head of research and development.
  • Tse has led R&D since March 2024; he previously served at CStone Pharmaceuticals, including as chief scientific officer and senior vice president.
  • Board appointed Ye as chief financial officer effective April 1, 2026, while he continues to oversee business development and global commercialization strategy.
  • Ye has served as interim CFO since January 2025; he previously held business development roles at inVentiv Health (now Syneos Health) and leadership posts at GenScript and Patheon.
  • Current president Kaiyang Tang will retire from role effective April 1, 2026, remaining with company as corporate strategy professor.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adlai Nortye Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-038551), on April 01, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment